Federated Hermes
RXRX icon

Federated Hermes’s Recursion Pharmaceuticals RXRX Stock Holding History

Federated Hermes’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-531
Closed -$2.69K – 2213
2025
Q2 		$2.69K Buy
+531
New +$2.61K ﹤0.01% 1943
2023
Q4 		– Sell
-20,000
Closed -$153K – 2185
2023
Q3 		$153K Buy
+20,000
New +$200K ﹤0.01% 1560

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $34.8B AUM 107.63% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's RXRX Position: Q3 2025 in Review

Federated Hermes sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 531 shares — an estimated $2.69K sold.

Federated Hermes first reported a position in RXRX in Q3 2023 and held it in 2 quarters. The position peaked at $153K in Q3 2023. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Federated Hermes reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 531 Recursion Pharmaceuticals shares in Q3 2025, an estimated $2.69K.
  • Federated Hermes first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Federated Hermes's Recursion Pharmaceuticals position peaked at $153K in Q3 2023.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.